Literature DB >> 29039555

miR-363 inhibits the growth, migration and invasion of hepatocellular carcinoma cells by regulating E2F3.

Junfeng Ye1, Wei Zhang1, Songyang Liu1, Yahui Liu1, Kai Liu1.   

Abstract

A growing body of evidence suggests that microRNA-363 (miR-363) plays crucial roles in tumor progression, development and metastasis, and confer resistance to chemotherapeutic drugs in several types of cancers. However, the biological function and underlying molecular mechanism of miR-363 in hepatocellular carcinoma (HCC) have not been fully elucidated. In the present study, we investigated the biological function and mechanism of miR-363 in the regulation of HCC progression. We found that miR-363 was downregulated in HCC cell lines and tissues, and a low expression level of miR-363 was associated with tumor differentiation, TNM stage and lymph node metastasis. Forced overexpression of miR-363 significantly suppressed HCC cell proliferation, migration, invasion and decreased epithelial‑mesenchymal transition (EMT) in vitro, as well as inhibited tumor growth in vivo. Analysis of the underlying mechanisms revealed that miR-363 regulated E2F transcription factor 3 (E2F3) expression by directly targeting its 3' untranslated region. E2F3 overexpression partially attenuated the tumor-suppressive effects of miR-363 in HCC cells. In addition, E2F3 expression was upregulated in the HCC tissues, and was negatively correlated with the level of miR-363 in human HCC tissues. Taken together, these results revealed that miR-363 is involved in HCC growth and invasion and functions as a tumor suppressor by negatively regulating E2F3.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29039555     DOI: 10.3892/or.2017.6018

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Role of E2Fs and mitotic regulators controlled by E2Fs in the epithelial to mesenchymal transition.

Authors:  Shirley Jusino; Harold I Saavedra
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-01

Review 2.  LncRNA-miRNA-mRNA regulatory axes in endometrial cancer: a comprehensive overview.

Authors:  Abhishek Shetty; Thejaswini Venkatesh; Shama Prasada Kabbekodu; Rie Tsutsumi; Padmanaban S Suresh
Journal:  Arch Gynecol Obstet       Date:  2022-02-18       Impact factor: 2.493

3.  Long non-coding RNA CASC9 promotes the progression of retinoblastoma via interacting with miR-145-5p.

Authors:  Ting Zhang; Jingpu Yang; Fangchao Gong; Lin Li; Aipeng Li
Journal:  Cell Cycle       Date:  2020-08-10       Impact factor: 4.534

4.  LncRNA OIP5-AS1 interacts with miR-363-3p to contribute to hepatocellular carcinoma progression through up-regulation of SOX4.

Authors:  Jianchu Wang; Qianli Tang; Libai Lu; Zongjiang Luo; Wenchuan Li; Yuan Lu; Jian Pu
Journal:  Gene Ther       Date:  2020-02-10       Impact factor: 5.250

5.  LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells.

Authors:  Qianqian Geng; Zhubin Li; Xintao Li; Yunhua Wu; Nanzheng Chen
Journal:  J Bioenerg Biomembr       Date:  2021-03-19       Impact factor: 2.945

6.  Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma.

Authors:  Yan-Lin Huang; Gang Ning; Lu-Biao Chen; Yi-Fan Lian; Yu-Rong Gu; Jia-Liang Wang; Dong-Mei Chen; Huan Wei; Yue-Hua Huang
Journal:  Cancer Manag Res       Date:  2019-02-19       Impact factor: 3.989

7.  Expression and gene regulation network of RBM8A in hepatocellular carcinoma based on data mining.

Authors:  Yan Lin; Rong Liang; Yufen Qiu; Yufeng Lv; Jinyan Zhang; Gang Qin; Chunling Yuan; Zhihui Liu; Yongqiang Li; Donghua Zou; Yingwei Mao
Journal:  Aging (Albany NY)       Date:  2019-01-22       Impact factor: 5.682

8.  MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.

Authors:  Yongtao Zhang; Fang Wang; Lina Wang; Quanbin Zhang
Journal:  World J Surg Oncol       Date:  2020-05-01       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.